CHOE MEDI |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-.--% | -.--% |
| 06-26 | Chordate Medical Holding AB Receives First Order from Switzerland | CI |
| 06-13 | Chordate Medical Holding AB Enters New Partnership Agreement with Neurolite AG | CI |
Business Summary
Sales per Business
| SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Neuromodulation Treatment Technology
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +799.66% |
Sales per region
| SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
International
50.6
%
| 0 | 44.9 % | 0 | 50.6 % | +913.93% |
European Union
49.4
%
| 0 | 55.1 % | 0 | 49.4 % | +706.59% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 14-10-31 | |
| Director of Finance/CFO | 56 | 17-10-01 | |
Jan Hermansson
CTO | Chief Tech/Sci/R&D Officer | 68 | 11-12-31 |
Jan Lindberg
CTO | Chief Tech/Sci/R&D Officer | 68 | 11-12-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 14-05-31 | |
Gunilla Lundmark
BRD | Director/Board Member | 61 | 17-03-31 |
| Chief Executive Officer | 63 | 14-10-31 | |
| Director/Board Member | 63 | 23-04-30 | |
| Chairman | 50 | 14-10-31 | |
| Director/Board Member | 45 | 21-09-30 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 488,087,865 | 224,552,867 ( 46.01 %) | 0 | 46.01 % |
Company contact information
Sector
Sales per region
| 1st Jan change | Capi. | |
|---|---|---|
| +4.71% | 212B | |
| +8.66% | 187B | |
| +27.03% | 155B | |
| +34.01% | 115B | |
| +2.17% | 65.5B | |
| +14.05% | 52.87B | |
| -3.30% | 45.25B | |
| -3.36% | 39.7B | |
| +6.48% | 37.72B |
- Stock Market
- Equities
- CMH Stock
- Stock
- Company CHOE MEDI
